tbuckley/cabot-search huggingface dataset:
Association of Filaggrin Loss of Function and Thymic Stromal Lymphopoietin Variation With Treatment Use in Pediatric Atopic Dermatitis
Authors: Joshua Chang, Nandita Mitra, Ole Hoffstad, David J. Margolis
Journal: JAMA Dermatology (2016)

<h3>Importance</h3> Atopic dermatitis (AD) is a common illness of childhood. <h3>Objective</h3> To determine whether variations in<i>FLG</i>and<i>TSLP</i>genotype corresponded to differences in treatment use over time. <h3>Design, Setting, and Participants</h3> This prospective cohort study recruited and followed a volunteer sample of 842 children enrolled in the Pediatric Eczema Elective Registry who provided saliva samples for DNA extraction for 10 years. Eligibility criteria included age 2 to 17 years, AD diagnosis without cancer, and prior pimecrolimus use. Participants were followed for an average of 7.6 years (approximately 6396 person-years); 138 patients (16.4%) had no missing data over 10 years of follow-up. <h3>Exposures</h3> Evaluation of<i>FLG</i>and<i>TSLP</i>genotypes. <h3>Main Outcomes and Measures</h3> Self-reported outcomes of whether a child's AD required the use of topical steroids, topical calcineurin inhibitors, or other medications within the past 6 months at 6-month intervals. <h3>Results</h3> Overall, 842 children (mean [SD] age, 1.9 [2.7] years; 438 girls) were included in this study. Treatment use among patients with 0, 1, or 2<i>FLG</i>loss of function (LOF) alleles was compared as well as those that were wildtype, heterozygous, or homozygous for the<i>TSLP</i>rs1898671single-nucleotide polymorphism. Patients with 2<i>FLG</i>LOF alleles were less likely to report skin clearance (odds ratio [OR], 0.20; 95% CI, 0.07-0.55) and more likely to use steroids (OR, 5.04; 95% CI, 1.91-13.31).<i>TSLP</i>rs1898671homozygotes were less likely to report topical calcineurin inhibitor use (OR, 0.16; 95% CI, 0.06-0.42), and among all patients that had discontinued topical calcineurin inhibitors, those with thers1898671single-nucleotide polymorphism were more likely to have stopped all other treatment as well (OR, 0.45; 95% CI, 0.26-0.76). In all but 1 of our comparisons, no significant difference between wildtype and heterozygous patients were found. <h3>Conclusions and Relevance</h3> Treatment use and likely effectiveness was associated with genetic variation. Variation was limited to children with 2<i>FLG</i>LOF alleles or<i>TSLP</i>rs1898671homozygotes, with no significant difference observed between wildtype and heterozygous patients in the majority of the outcomes studied. Therefore, the key differentiating factor in our analyses was the number of<i>FLG</i>LOF alleles or<i>TSLP</i>SNPs rather than the absolute presence or absence of these variants. This may be an important consideration for future studies.
Nuclear Localization of Codanin-1, a Product of a Newly Identified Gene Mutated in Congenital Dyserythropoeitic Anemie Type I.
Authors: Hannah Tamary, Naama Chernikovsk, Sharon Lotan, Tali Edlitz-Markus, Hanna Shalev, Sigal Shaklai, Eithan Fibach, Isaac Yaniv, Peretz Resnitszky, Orly Dgany
Journal: Blood (2004)
Validation of CLL FISH Panel Scoring by Members of the Chronic Lymphocytic Leukemia Research Consortium.
Authors: Stephanie A. Smoley, Daniel L. Van Dyke, Neil E. Kay, Nyla A. Heerema, Marie L. dell’ Aquila, Prasad Koduru, Paola Dal Cin, Laura Rassenti, John C. Byrd, Kanti R. Rai, Jennifer R. Brown, Andrew W Greaves, Thomas J. Kipps, Gordon W. Dewald
Journal: Blood (2008)
Autologous Hematopoietic Stem Cell Transplantation Following a Uniform Modified BEAM Conditioning Regimen for Hodgkin's Lymphoma – Prognostic Factors and Long-Term Outcomes.
Authors: Anna Czyz, Anna Lojko, Lidia Gil, Dominik Dytfeld, Danuta Drozdowska, Adam Nowicki, Maria Kozlowska, Krzysztof Sawinski, Jan Styczynski, Mieczyslaw Komarnicki
Journal: Blood (2009)
Macroscopic inflammatory tracheal and endobronchial nodules in Sjögren's syndrome
Authors: Hiromichi Hara, Kazuyoshi Kuwano, Shunsuke Minagawa, Takanori Numata, Jun Araya, Katsutoshi Nakayama
Journal: Thorax (2016)

A 38-year-old woman with primary Sjogren's syndrome (SS) presented with a 1 month history of cough and chest pain. She had been treated with prednisolone for organising pneumonia and had been on prednisolone (5 mg/day). Flexible bronchoscopy revealed macroscopic multiple nodules mainly in trachea and in both main bronchus (figure 1A). Three-dimensional CT (3D-CT) also demonstrated multiple nodules in the same place (figure 1B). Endobronchial biopsy showed polyclonal lymphocyte infiltration in the bronchial submucosa and epithelium in part (figure 1C, H & E: upper, CD3: middle, CD20: lower). There were few IgG4-positive plasma cells in the lesion. Amyloid …
Vaccination with Host Dendritic Cells Induces Graft-Versus-Leukemia Responses without Severe Graft-Versus-Host Disease in a Preclinical Mouse Model for Allogeneic Stem Cell Transplantation.
Authors: Robbert van der Voort, Jurjen Ruben, Annemieke Vos, Marielle Philippens, T.M. de Witte, Harry Dolstra
Journal: Blood (2006)
Two Cases of Chronic Active Epstein-Barr Virus Infection (CAEBV) Successfully Treated with Allogeneic Bone Marrow Transplantation and Induction of Specific Cytotoxic T Lymphocyte (CTL).
Authors: Takako Miyamura, Kousuke Chayama, Tomoaki Wada, Kazunari Yamaguchi, Nobuko Yamashita, Toshiaki Ishida, Kana Washio, Naoto Morishita, Megumi Oda, Tsuneo Morishima
Journal: Blood (2007)
Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses
Authors: Martha Q. Lacy, Betsy R. LaPlant, Kristina M Laumann, Shaji Kumar, Morie A Gertz, Suzanne R Hayman, Francis Buadi, Angela Dispenzieri, John A Lust, Prashant Kapoor, Nelson Leung, Stephen Russell, David Dingli, Ronald S. Go, Wilson I Gonsalves, Rafael Fonseca, P. Leif Bergsagel, Vivek Roy, Taimur Sher, Sikander Ailawadhi, Asher Chanan-Khan, A. Keith Stewart, Craig B. Reeder, S. Vincent Rajkumar, Joseph R. Mikhael
Journal: Blood (2014)
Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures
Authors: Guillermo Garcia-Manero, Hui Yang, Zhihong Fang, Hagop M. Kantarjian, Courtney D. DiNardo, Elias J. Jabbour, Naveen Pemmaraju, Naval Daver, Ricardo Delumpa, Christopher Loiselle, Silvia Rivera, Kristin Anderson, Brittany Yearby, Susan Denton, Whitney Smith, Kathleen Tiefenwerth, Hiroyuki Iwamura, Teletha Gipson, Michele Rosner, Thomas J. Myers, Linda J. Paradiso
Journal: Blood (2016)
Abstract 2545: Effect of aldehydes in anthracycline cytotoxicity in S. cerevisiae
Authors: Jana S. Miles, Tryphon K. Mazu, Hernan Flores-Rozas
Journal: Cancer Research (2015)

Abstract Anthracyclines constitute drugs of choice as single agents or in combination therapy in cancers that are refractory to other therapies, such as triple negative breast cancer, commonly observed in African-American women (AA) and is characterized for lacking biomarkers for targeted therapy, and for being aggressive and carrying bad prognoses. Anthracyclines effectiveness is dose-dependent, which increases the risk of side-effects and eventually the development of drug resistance. In S. cerevisiae, mutants of HOM6 display hypersensitivity to doxorubicin by inactivation of the homoserine dehydrogenase. We hypothesized that the L-aspartate-semialdehyde accumulating at this step, sensitizes the cells to anthracyclines. We confirmed this by inactivating HOM3, a prior step in the threonine biosynthesis pathway which prevents the accumulation of the L-aspartate-semialdehyde, rescuing the hom6 strain. To expand our knowledge of the relationship between aldehydes and anthracyclines, we sought to identify other aldehydes that can enhance the toxic effects of doxorubicin. We exposed S. cerevisiae to aldehydes (acetaldehyde, formaldehyde and glutaraldehyde) alone and combined with doxorubicin, cisplatin and menadione. Combination of formaldehyde (2 mM) and doxorubicin was most effective at reducing cell survival by between 31 to 39-fold (in wild type cells) relative to doxorubicin and formaldehyde alone. This effect was dose-dependent on doxorubicin. Co-treatment with formaldehyde and doxorubicin also showed increased toxicity in anthracycline-resistant strains siz1 and msh2. Combination of formaldehyde (2 mM) and menadione (60 mM) reduced cell survival by between 1- to 1.5-fold in wild type cells. Combination of acetaldehyde (2 mM) and menadione (60 mM) reduced cell survival by between 1.6- to 2.2-fold in wild type cells. Wild type cells treated with the combination of cisplatin (80 μM) and acetaldehyde (2 mM) or glutaraldehyde (2 mM) showed a reduced cell survival by between 0.4- to 3.12-fold with the combination of cisplatin and glutaraldehyde being the more cytotoxic of the two. Acetaldehyde, formaldehyde and glutaraldehyde show enhanced toxicity of wild type cells when combined with cytotoxic drugs. The potential use of a combination of aldehydes and cytotoxic drugs could potentially lead to applications intended to enhance anthracycline-based therapy. Citation Format: Jana S. Miles, Tryphon K. Mazu, Hernan Flores-Rozas. Effect of aldehydes in anthracycline cytotoxicity in S. cerevisiae. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2545. doi:10.1158/1538-7445.AM2015-2545
The role of non-invasive cardiovascular imaging in the assessment of cardiovascular risk in rheumatoid arthritis: where we are and where we need to be
Authors: Graham J Fent, John P Greenwood, Sven Plein, Maya H Buch
Journal: Annals of the Rheumatic Diseases (2016)

This review assesses the risk assessment of cardiovascular disease (CVD) in rheumatoid arthritis (RA) and how non-invasive imaging modalities may improve risk stratification in future. RA is common and patients are at greater risk of CVD than the general population. Cardiovascular (CV) risk stratification is recommended in European guidelines for patients at high and very high CV risk in order to commence preventative therapy. Ideally, such an assessment should be carried out immediately after diagnosis and as part of ongoing long-term patient care in order to improve patient outcomes. The risk profile in RA is different from the general population and is not well estimated using conventional clinical CVD risk algorithms, particularly in patients estimated as intermediate CVD risk. Non-invasive imaging techniques may therefore play an important role in improving risk assessment. However, there are currently very limited prognostic data specific to patients with RA to guide clinicians in risk stratification using these imaging techniques. RA is associated with increased risk of CV mortality, mainly attributable to atherosclerotic disease, though in addition, RA is associated with many other disease processes which further contribute to increased CV mortality. There is reasonable evidence for using carotid ultrasound in patients estimated to be at intermediate risk of CV mortality using clinical CVD risk algorithms. Newer imaging techniques such as cardiovascular magnetic resonance and CT offer the potential to improve risk stratification further; however, longitudinal data with hard CVD outcomes are currently lacking.
Quantitative Monitoring of NPM1A Mutations Can Be Used to Guide Immunotherapeutic Interventions After Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
Authors: Jessica C. Harskamp, Joya E. Nahon, Andrea M. Siegel, Hans L. Vos, Piëette P. Deutz-Terlouw, J.Hendrik Veelken, J.H. Frederik Falkenburg, Erik W.A. Marijt
Journal: Blood (2011)
Pilot Clinical Study Incorporating Hyperbaric Oxygen into Umbilical Cord Blood Transplantation
Authors: Omar S. Aljitawi, Siddhartha Ganguly, Tara L. Lin, Shana L Palla, Lominska Chris, Yu Qing, Jennifer Bunch, Megan Swink, Stacy Supancic, Anurag K. Singh, Sunil Abhyankar, Dennis Allin, Joseph P McGuirk
Journal: Blood (2014)
Clinical Activity of Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients
Authors: Carlo B Gambacorti-Passerini, Ilaria Dilda, Giovanni Giudici, Alessandra Perego, Francesca Pavesi, Luca Guerra, Lorenza Borin, Ivana Casaroli, Marilena Fedele, Luisa Verga, Enrico Maria Pogliani
Journal: Blood (2010)
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium
Authors: Giorgia Simonetti, Antonella Padella, Ítalo Faria do Valle, Marco Manfrini, Cristina Papayannidis, Carmen Baldazzi, Maria Chiara Fontana, Viviana Guadagnuolo, Anna Ferrari, Elisa Zago, Marianna Garonzi, Simona Bernardi, Emanuela Ottaviani, Annalisa Astolfi, Maria Chiara Abbenante, Giovanni Marconi, Simona Soverini, Michele Cavo, Nicoletta Testoni, Alberto Ferrarini, Massimo Delledonne, Torsten Haferlach, Daniel Remondini, Ilaria Iacobucci, Giovanni Martinelli
Journal: Blood (2015)
Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Scores Correlates with Increased Readmissions and Days In Hospital In Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplant
Authors: Szwed A. Ellen, Jack W. Hsu, Wei Hou, Randy A. Brown, Christopher R. Cogle, John W. Hiemenz, W. Stratford May JR, Jan S. Moreb, Baldeep Wirk, John R. Wingard
Journal: Blood (2010)
Comprehensive Analysis of Genetic Alterations in Acute Myeloid Leukemia According to the WHO Classification.
Authors: Yuichi Ishikawa, Hitoshi Kiyoi, Akane Tsujimura, Yasusi Miyazaki, Masao Tomonaga, Kazutaka Kuriyama, Syuichi Miyawaki, Tomoki Naoe
Journal: Blood (2007)
Allogeneic Transplant in Patients with Poor Prognosis B-Chronic Lymphocytic Leukemia (B-CLL): Comparative Study between Myeloablative(M) and Non-Myeloablative(NM) Conditioning Regimen.
Authors: M.D. Caballero, J.A. García-Marco, R. Martino, J. Esteve, M.V. Mateos, A. León, J. Sarrá, Josep Maria Ribera, G. Sanz, J. de la Serna, J.L. Díez, J.F. San Miguel11
Journal: Blood (2004)
Stem Cell Source Dependent Differences in Reconstituting Peripheral T Follicular Helper Cells Following Hematopoietic Cell Transplantation, Their Association with Chronic Gvhd and Role in Response to Influenza Vaccination
Authors: David A. Knorr, Ryan W Nelson, Ryan Shanley, Nicole Karras, Jeffrey S. Miller, John E Wagner, Bruce R. Blazar, Michael R. Verneris
Journal: Blood (2014)
Mti-101 (cyclized HYD1) Binds to CD44 and Induces Necrotic Cell Death in Multiple Myeloma
Authors: Anthony W. Gebhard, Rajesh R Nair, Michael Emmons, Priyesh R Jain, Andreas Becker, John Koomen, Ernst Schonbrunn, Daniel M Sullivan, Mark L McLaughlin, Lori A Hazlehurst
Journal: Blood (2012)
Outcome of Treatment after First Relapse in Adults Patients with Acute Lymphoblastic Leukemia (ALL) Initially Treated by the LALA-94 Trial.
Authors: Emmanuelle Tavernier, Jean-Michel Boiron, Francoise Huguet, Kenneth Francis Bradstock, Norbert Vey, Tibor Kovacsovics, Andre Delannoy, Nathalie Fegueux, Pierre Fenaux, Aspasia Stamatoullas, Olivier Tournilhac, Agnes Buzyn, Oumedaly Reman, Christiane Charrin, Claude Boucheix, Jean Gabert, Veronique Lheritier, Jean-Paul Vernant, Xavier Thomas
Journal: Blood (2006)
Polymorphisms of Thymidylate Synthase in the 5′- and 3′-Untranslated Regions Associated with Risk of Non-Hodgkin’s Lymphoma.
Authors: Hee Nam Kim, Huong Thi Thanh Tran, Il-Kwon Lee, Yeo-Kyeoung Kim, Deok-Hwan Yang, Je-Jung Lee, Myung-Geun Shin, Hoon Kook, Tai Ju Hwang, Moo Rim Park, Deog Yeon Jo, Jong Ho Won, HyeoungJoon Kim
Journal: Blood (2006)
The Presence of Moderate to High Donor-Specific Anti-HLA Antibody Titers Is Associated with a High Risk of Graft Failure in Haploidentical Stem Cell Transplantation
Authors: Stefan O Ciurea, Marcos De Lima, Pedro Cano, Martin Korbling, John McMannis, Sergio A Giralt, Borje S Andersson, Elizabeth J. Shpall, Richard E Champlin, Marcelo Fernandez-Vina
Journal: Blood (2008)
Relationship between Seroresponse to Epstein-Barr Virus and Survival in Patients with Lymphoid Malignancies.
Authors: E. Domingo-Domenech, J. Middeldorp, E. Gonzalez-Barca, Y. Benavente, V. Romagosa, R. Font, A. Fernandez de Sevilla, C. J. Meijer, S. de Sanjose
Journal: Blood (2005)
Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with Individualized Protocol Adjusted to the Status of Minimal Residual Disease and Age. Interim Analysis of PALG ALL 5–2007 Study
Authors: Sebastian Giebel, Jerzy Holowiecki, Malgorzata Krawczyk-Kulis, Krystyna Jagoda, Jaroslaw Piszcz, Monika Paluszewska, Maria Adamczyk-Cioch, Anna Ejduk, Anna Czyz, Beata Piatkowska-Jakubas, Ewa Lech-Maranda, Beata Stella-Holowiecka, Monika Szarejko, Slawomira Kyrcz-Krzemien, Janusz Kloczko, Wieslaw Wiktor Jedrzejczak, Anna Dmoszynska, Krzysztof Warzocha, Mieczyslaw Komarnicki, Aleksander Skotnicki, Tadeusz Robak, Andrzej Hellmann, Barbara Zdziarska, Kazimierz Sulek, Maria Domagala, Malgorzata Razny, Krystyna M Zawilska, Jolanta Starzak-Gwozdz
Journal: Blood (2010)
The αIIbP258S, a Newly Identified Mutation, and the αIIbG349D Substitutions Cause Glanzmann Thrombasthenia by Impairing αIIb-β3 Association in the Endoplasmic Reticulum.
Authors: Andrea Artoni, Federica Gelain, Abdolreza Afrasiabi, Maurizio Margaglione, Pier M. Mannucci
Journal: Blood (2006)
Enriched Expression of the Lymphatic Marker VEGFR-3 in CD56+ Cells with Low Levels of Lytic Function in Acute Myeloid Leukemia,
Authors: Ji Yoon Lee, Heeje Kim, Sohye Park, Seung-Ah Yahng, Jae-Ho Yoon, Seung-Hwan Shin, Woo-Sung Min
Journal: Blood (2011)
The Efficacy and Long-Term Toxicity of Intravenous Busulfan and Cyclophosphamide Conditioning Regimen for Stem Cell Transplantation in Advanced Lymphoma.
Authors: Edgardo S. Santos, Teresa DeCesare, Mark Goodman, Joseph D. Rosenblatt, Denise L. Pereira, Hugo F. Fernandez
Journal: Blood (2004)
Differences in Cyto- and Molecular Genetic Abnormalities between Children &amp;lt;2 Years and Older Children with Acute Myeloid Leukemia.
Authors: Brian V. Balgobind, Iris H. Hollink, Dirk Reinhardt, Jutta Bradtke, Andrea Teigler-Schlegel, Anne R. von Bergh, Jacqueline Cloos, Gertjan J. Kaspers, Elisabeth van Wering, Z. Zemanova, Jan Stary, Jean-Michel Cayuela, Andre Baruchel, Marry M. van den Heuvel-Eibrink, Christian M. Zwaan
Journal: Blood (2007)
A Multicenter Prospective Randomized Study Testing Non-Inferiority of Thalidomide 100 mg/day as Compared with 400 mg/day in Patients with Refractory/Relapsed Multiple Myeloma: First Results of the Final Analysis of the IFM 01-02 Study.
Authors: Ibrahim Yakoub-Agha, C. Hulin, C. Doyen, L. Benboubker, L. Voillat, K. Bouabdallah, G. Guillerm, P. Moreau, F. Maloisel, A.M. Stoppa, B. Pegourie, P. Rodon, M. Dib, P. Casassus, B. Slama, E. Voog, H. Jardel, P. Collet, M. Wettervald, A.M. Peny, P. Mineur, C. Duguet, R. Zerbib, T. Facon, J.Y. Mary
Journal: Blood (2005)
Biochemical Characterization and Gene Expression Profiling of Cytarabine Treated Stromal Fibroblasts Reveal Regulatory Mechanisms Affecting Hyaluronan and Heparan Sulfate Proteoglycans.
Authors: Sonja Zweegman, Floortje L. Kessler, Ron Kerkhoven, Mike Heimerikx, Peter C. Huijgens, Angelika M. Drager, Jacob van den Born
Journal: Blood (2004)
The Impact of Anti-HLA Antibodies on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes After Reduced-Intensity Conditioning Regimens
Authors: Marie Y. Detrait, Valerie Dubois, Mohamad Sobh, Stephane Morisset, Nathalie Tedone, Franck E. Nicolini, Helene Labussiere, Lilia Gillis, Fiorenza Barraco, Giovanna Cannas, Sophie Ducastelle, Jihane Fattoum, Xavier Thomas, Youcef Chelghoum, Mauricette Michallet
Journal: Blood (2011)
T Cell Depletion with Alemtuzumab Is Associated with a High Incidence of EBV Viraemia but Low Risk of PTLD Following Allogeneic Stem Cell Transplantation
Authors: Ben Carpenter, Maria Dimopoulou, Nilusha Manji, Tanzina Haque, Claire Atkinson, Sarah Grace, Stephen Mackinnon, Ronjon Chakraverty
Journal: Blood (2008)
Suppression of Inflammatory Arthritis by Human Gut‐Derived<i>Prevotella histicola</i>in Humanized Mice
Authors: Eric V. Marietta, Joseph A. Murray, David H. Luckey, Patricio R. Jeraldo, Abhinav Lamba, Robin Patel, Harvinder S. Luthra, Ashutosh Mangalam, Veena Taneja
Journal: Arthritis & Rheumatology (2016)

The gut microbiome regulates host immune homeostasis. Rheumatoid arthritis (RA) is associated with intestinal dysbiosis. This study was undertaken to test the ability of a human gut-derived commensal to modulate immune response and treat arthritis in a humanized mouse model.We isolated a commensal bacterium, Prevotella histicola, that is native to the human gut and has systemic immune effects when administered enterally. Arthritis-susceptible HLA-DQ8 mice were immunized with type II collagen and treated with P histicola. Disease incidence, onset, and severity were monitored. Changes in gut epithelial proteins and immune response as well as systemic cellular and humoral immune responses were studied in treated mice.When treated with P histicola in prophylactic or therapeutic protocols, DQ8 mice exhibited significantly decreased incidence and severity of arthritis compared to controls. The microbial mucosal modulation of arthritis was dependent on regulation by CD103+ dendritic cells and myeloid suppressors (CD11b+Gr-1+ cells) and by generation of Treg cells (CD4+CD25+FoxP3+) in the gut, resulting in suppression of antigen-specific Th17 responses and increased transcription of interleukin-10. Treatment with P histicola led to reduced intestinal permeability by increasing expression of enzymes that produce antimicrobial peptides as well as tight junction proteins (zonula occludens 1 and occludin). However, the innate immune response via Toll-like receptor 4 (TLR-4) and TLR-9 was not affected in treated mice.Our results demonstrate that enteral exposure to P histicola suppresses arthritis via mucosal regulation. P histicola is a unique commensal that can be explored as a novel therapy for RA and may have few or no side effects.
Realizing the Promise of Parity Legislation for Mental Health
Authors: Richard G. Frank
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal